Search company, investor...


Founded Year



Debt | Dead

Total Raised


Last Raised


About Fimea

Provider of services for nanometer surface structuring of athermal micro-materials using UV lasers. The company conducts research in the area of processes induced by photons for material modification, technology development for special micro-material processing, as well as material and structure characterizing.

Headquarters Location

Agastrasse 24

Berlin, 12489,


49 30 67198712

Missing: Fimea's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Fimea's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Fimea News

Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland

Oct 18, 2022

Vancouver, Vancouver, BC , Oct. 18, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”), an actively managed, psychedelics industry-focused investment issuer, today announced that one of its portfolio companies, Clairvoyant Therapeutics (“Clairvoyant”), has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company's Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland. The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET). Following the approval from FIMEA, Clairvoyant has launched the first of four planned trial sites in Finland. In total, the clinical trial will be initiated in approximately 15 sites across Canada and Europe with the first site in Canada initiated in June of 2022. Several potential patients have already entered the screening process for the trial. “Clairvoyant’s goal is to obtain approval for AUD-related psilocybin therapy in Europe, the UK, and Canada by 2026, and they have taken another step toward achieving that goal,” stated Alex Somjen, CEO of Origin. “The team at Origin is really pleased with their progress thus far.” About Clairvoyant Therapeutics Clairvoyant Therapeutics is a Canadian biotechnology company changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the E.U., the U.K., and Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026. The company’s exceptional team, with a proven clinical track record and deep drug development experience, has made Clairvoyant the most advanced company globally developing psilocybin therapy for the treatment of AUD. Clairvoyant is committed to meeting the highest standards of verified social and environmental performance, public transparency and legal accountability to balance profit and purpose and is a pending B Corporation Certification. Clairvoyant is a member of Life Science BC and Biotechnology Innovation Organization (BIO). Learn more at and follow the Company on LinkedIn and Twitter . About Origin Therapeutics Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Learn more at

Fimea Frequently Asked Questions (FAQ)

  • When was Fimea founded?

    Fimea was founded in 1996.

  • Where is Fimea's headquarters?

    Fimea's headquarters is located at Agastrasse 24, Berlin.

  • What is Fimea's latest funding round?

    Fimea's latest funding round is Debt.

  • How much did Fimea raise?

    Fimea raised a total of $880K.

  • Who are the investors of Fimea?

    Investors of Fimea include TBG and IKB Private Equity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.